These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11966713)

  • 1. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis.
    Fischer M; Fiedler E; Marsch WC; Wohlrab J
    Br J Dermatol; 2002 Apr; 146(4):707-9. PubMed ID: 11966713
    [No Abstract]   [Full Text] [Related]  

  • 2. Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab.
    Kreft B; Wohlrab J; Bramsiepe I; Eismann R; Winkler M; Marsch WC
    J Dermatol; 2010 Oct; 37(10):904-6. PubMed ID: 20860742
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe cutaneous adverse reactions to drugs.
    Chia FL; Leong KP
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis.
    Wojtkiewicz A; Wysocki M; Fortuna J; Chrupek M; Matczuk M; Koltan A
    Acta Derm Venereol; 2008; 88(4):420-1. PubMed ID: 18709327
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.
    White JC; Appleman S
    Pediatrics; 2014 Oct; 134(4):e1194-8. PubMed ID: 25246624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.
    Paquet P; Jennes S; Rousseau AF; Libon F; Delvenne P; Piérard GE
    Burns; 2014 Dec; 40(8):1707-12. PubMed ID: 24726294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric toxic epidermal necrolysis treated successfully with infliximab.
    Chafranska L; Saunte DM; Behrendt N; Nygaard U; Christensen RJ; Sand C; Jemec GB
    Pediatr Dermatol; 2019 May; 36(3):342-345. PubMed ID: 30834560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic epidermal necrolysis in a child successfully treated with infliximab.
    Scott-Lang V; Tidman M; McKay D
    Pediatr Dermatol; 2014; 31(4):532-4. PubMed ID: 23072342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis.
    Woolridge KF; Boler PL; Lee BD
    Cutis; 2018 Jan; 101(1):E15-E21. PubMed ID: 29529123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases.
    Meiss F; Helmbold P; Meykadeh N; Gaber G; Marsch WCh; Fischer M
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):717-9. PubMed ID: 17448012
    [No Abstract]   [Full Text] [Related]  

  • 11. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.
    Zhang S; Tang S; Li S; Pan Y; Ding Y
    J Dermatolog Treat; 2020 Feb; 31(1):66-73. PubMed ID: 30702955
    [No Abstract]   [Full Text] [Related]  

  • 12. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Koh MJ; Tay YK
    Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive hypertrophic scarring after toxic epidermal necrolysis in a child.
    Kreft B; Lieser U; Haase R; Marsch WC; Wohlrab J
    Pediatr Dermatol; 2014; 31(4):527-8. PubMed ID: 23025572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
    Brunasso AM; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):70-1. PubMed ID: 21103830
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study.
    Mohanty S; Das A; Ghosh A; Sil A; Gharami RC; Bandyopadhyay D; Das NK
    Indian J Dermatol Venereol Leprol; 2017; 83(3):312-316. PubMed ID: 28366923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of severe psoriasis to infliximab.
    Mang R; Stege H; Ruzicka T; Krutmann J
    Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
    Cocco A; Angelucci E; Viscido A; Caprilli R
    Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab therapy failure in two patients with pemphigus vulgaris.
    García-Rabasco A; Alsina-Gibert M; Pau-Charles I; Iranzo P
    J Am Acad Dermatol; 2012 Nov; 67(5):e196-7. PubMed ID: 23062908
    [No Abstract]   [Full Text] [Related]  

  • 19. Infliximab in the management of severe pemphigus vulgaris.
    Pardo J; Mercader P; Mahiques L; Sanchez-Carazo JL; Oliver V; Fortea JM
    Br J Dermatol; 2005 Jul; 153(1):222-3. PubMed ID: 16029365
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of infliximab in toxic epidermal necrolysis: a still opened challenge.
    Ganzetti G; Campanati A; Simonetti O; Giuliodori K; Giangiacomi M; Lemme G; Offidani A
    G Ital Dermatol Venereol; 2015 Aug; 150(4):467-71. PubMed ID: 25394212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.